Literature DB >> 10393212

Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.

T M Forte1, M N Oda, L Knoff, B Frei, J Suh, J A Harmony, W D Stuart, E M Rubin, D S Ng.   

Abstract

Lecithin:cholesteryl acyltransferase (LCAT) deficiency resulting from targeted disruption of the Lcat gene in the mouse is associated with dramatic decreases in HDL concentration and the accumulation of nascent HDL in the plasma. We examined whether LCAT deficiency in mice is associated with a concomitant decrease in two antioxidative enzymes, paraoxonase (PON) and platelet-activating factor acetylhydrolase (PAF-AH). In control Lcat (+/+) mice both these enzymes are transported on HDL. Compared to Lcat (+/+) mice, HDL-cholesterol is reduced 94% and apoA-I, 90%, in Lcat (-/-) mice; this reduction in HDL is paralleled by a 71% decrease in PAF-AH activity and in a 58% decrease in PON activity. Apolipoprotein J (apoJ) levels, rather than being decreased, were significantly (P = 0.01) higher (36%) in Lcat (-/-) than in Lcat (+/+) mice, and the apo J/PON ratio was 3-fold greater in Lcat (-/-) than in Lcat (+/+) animals. Even though apolipoprotein A-I (apoA-I) concentration and PON activity were drastically reduced, there was no reduction in apoA-I and PON liver mRNA levels suggesting that post-transcriptional events are responsible for the reduction of plasma PON and apoA-I levels. Fast protein liquid chromatography (FPLC) revealed that in Lcat (+/+) mice both PON and PAF-AH activity is associated with large, apoA-I-containing HDL particles (9.7 nm by non-denaturing gradient gel electrophoresis) while in Lcat (-/-) mice both enzymes are associated with small 8.2 nm particles. We conclude that the concomitant reduction in HDL and apoA-I concentrations and PON and PAF-AH activities is best explained by rapid clearance of the small HDL particles found in LCAT deficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393212

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Authors:  Fatiha Tabet; Alan T Remaley; Aude I Segaliny; Jonathan Millet; Ling Yan; Shirley Nakhla; Philip J Barter; Kerry-Anne Rye; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

Review 3.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

4.  Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I.

Authors:  Ricardo Carnicer; María A Navarro; Natalia Guillén; José M Arbonés-Mainar; Joaquín C Surra; Sergio Acín; Jesús Osada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-26       Impact factor: 3.000

5.  Serum Basal Paraoxonase 1 Activity as an Additional Liver Function Test for the Evaluation of Patients with Chronic Hepatitis.

Authors:  Anand K Pyati; Chandrakanth K Halappa; Sudharani A Pyati; Vinod Wali
Journal:  J Clin Diagn Res       Date:  2015-11-01

Review 6.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Authors:  Xavier Rousset; Boris Vaisman; Marcelo Amar; Amar A Sethi; Alan T Remaley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

7.  Exploring the factors that affect blood cholesterol and heart disease risk: is dietary cholesterol as bad for you as history leads us to believe?

Authors:  Mitchell M Kanter; Penny M Kris-Etherton; Maria Luz Fernandez; Kasey C Vickers; David L Katz
Journal:  Adv Nutr       Date:  2012-09-01       Impact factor: 8.701

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.